Century Therapeutics (IPSC) vs Protalix BioTherapeutics (DE) (PLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Century Therapeutics (IPSC) has outperformed Protalix BioTherapeutics (DE) (PLX) over the past year, gaining 137.8% versus a gain of 65.7%. Over five years, PLX leads with a +192.9% price change compared with -93.2% for IPSC. Protalix BioTherapeutics (DE) is the larger company by market cap ($244.5 million vs $211.6 million), about 1.2 times the size, while Century Therapeutics is growing revenue faster (+1556.8% vs -1.2%).
Century Therapeutics converts more of its revenue into profit, with a net margin of -8.8% versus -12.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPSC | PLX |
|---|---|---|
| Share price | $1.17 | $2.90 |
| Market cap | $211.56M | $244.52M |
| 1-day change | -11.74% | -5.23% |
| YTD return | +17.09% | +61.11% |
| 1-year return | +137.76% | +65.71% |
| 5-year return | -93.23% | +192.93% |
| P/E ratio (TTM) | — | 12.08 |
| Forward P/E | — | 4.68 |
| EPS (TTM) | $-0.64 | $0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $109.16M | $52.74M |
| Revenue growth (YoY) | +1556.76% | -1.23% |
| Net income (latest FY) | $-9.58M | $-6.60M |
| Gross margin | — | 48.82% |
| Operating margin | -15.82% | -10.43% |
| Net margin | -8.78% | -12.52% |
| 52-week high | $3.04 | $3.19 |
| 52-week low | $0.48 | $1.65 |
| Distance from 52-week high | -61.68% | -9.09% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +307.73% | +313.79% |
| Average volume | 759.69K | 903.48K |
| Shares outstanding | 181.60M | 84.32M |
| Employees | 78 | 226 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed PLX by 72.0 percentage points over the past year.
- Century Therapeutics grew revenue faster in its latest fiscal year (+1556.76% vs -1.23%).
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees
IPSC vs PLX FAQ
Which is bigger, Century Therapeutics or Protalix BioTherapeutics (DE)?
Protalix BioTherapeutics (DE) (PLX) is larger, with a market capitalization of $244.52M compared with $211.56M for Century Therapeutics (IPSC).
Which stock has performed better over the past year, IPSC or PLX?
IPSC returned +137.76% over the past 12 months, compared with +65.71% for PLX (price return, excluding dividends). Past performance does not predict future results.
Are Century Therapeutics and Protalix BioTherapeutics (DE) in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.